Tegio has relatively good results in the treatment of pancreatic cancer and should be used in accordance with medical advice.
The commonly used dosage forms of Tegio are capsules and tablets. It is used for unresectable metastatic or locally advanced gastric cancer. Clinical studies have shown that Tegio also has relatively better efficacy in pancreatic cancer, but pancreatic cancer is a tumor of high malignancy and is relatively difficult to treat.
Adverse reactions of Tegio include leukopenia, neutropenia, thrombocytopenia, anemia, loss of appetite, nausea, vomiting, stomatitis, diarrhea, fatigue, hyperpigmentation, and skin rash.
The drug is contraindicated in people with a history of severe allergy to the product, severe bone marrow suppression, severe renal function abnormalities, and severe hepatic function abnormalities. The drug should be used rationally under the guidance of a doctor.